The past decade has witnessed significant transformations in healthcare infrastructure, driven by the widespread adoption of technology and innovative medical devices. With the rising prevalence of infectious and chronic diseases, the demand for disinfection and sterilization equipment has reached a critical level. The urgency to effectively combat these diseases has underscored the importance of advanced equipment for disinfection and sterilization, highlighting their indispensable role in modern healthcare practices.
According to Data Bridge Market Research, the Hospital Acquired Infection Control Market accounted for USD 29.1 billion in 2021 and is expected to reach USD 34.10 billion by 2029. The market is expected to grow with a CAGR of 9.90% in the forecast period of 2022 to 2029.
“Rise in the prevalence of hospital-acquired infections (HAIs) propelling the market’s growth”
The rise in hospital-acquired infections is attributed to inadequate preventive measures. Contamination of medical equipment and devices remains a significant cause of infections in healthcare settings. Consequently, there will be an escalated demand for the hospital-acquired infection control market. The need to address this pressing issue drives the growth of measures and solutions to prevent and control infections acquired within hospitals.
What restraints the growth of the hospital acquired infection control market?
“Increased cost of endoscopy reprocessing restraints the market’s growth”
The hospital acquired infection control market is facing constraints in its growth due to the increased cost of endoscopy reprocessing. As hospitals strive to implement stringent infection control measures, the expenses associated with reprocessing endoscopic equipment have risen significantly. These elevated costs pose a challenge to healthcare facilities, impacting their ability to invest in comprehensive infection control solutions. Therefore, the increased financial burden limits the market's expansion
Segmentation: Hospital Acquired Infection Control Market
The hospital acquired infection control market is segmented on the basis of product, application, technology, disease and end users.
- On the basis of product, the hospital acquired infection control market has been segmented into sterilizers, disinfectors, endoscope reprocessors, microbial testing instruments, reagents, consumables, disinfectants, infection prevention and surveillance software, and others.
- On the basis of application, the hospital acquired infection control market has been segmented into disease testing, and drug-resistance testing.
- 根據技術，醫院獲得性感染控制市場細分為表型方法和基因型方法。
- 根據疾病類型，醫院獲得性感染控制市場細分為醫院獲得性肺炎、血液感染、手術部位感染、胃腸道感染、泌尿道感染等。
- 對於最終用戶而言，醫院感染控制市場已細分為醫院、ICU、門診手術、診斷中心、療養院、婦產中心等。
區域洞察：北美主導醫院獲得性感染控制市場
由於主要醫療機構和當局越來越注重預防和控制來自各種醫療環境的感染，北美在醫院獲得性感染控制市場佔據主導地位。此外，公眾對醫院內感染的認識不斷提高將有助於該地區市場在整個預測期內的擴張。
由於中低收入國家醫院內感染發生率激增，加上醫療基礎設施的進步，預計亞太地區的醫院內感染控制市場將大幅成長。其次，與已開發國家相比，這些已開發國家的新生兒面臨更大的感染醫療相關感染的風險。預計這些因素將在未來幾年推動該地區醫院感染控制市場的成長。
要了解有關該研究的更多信息，請訪問：https://www.databridgemarketresearch.com/reports/global-hospital-acquired-infection-control-market
近期發展
- 2021年9月，索迪斯擴大了與美國藝康的合作，透過Protecta Plus計畫控制醫院內感染。該計劃旨在利用 Ecolab 的 Bioquell 過氧化氫蒸汽技術來降低醫院和醫療機構的感染風險。
醫院獲得性感染控制市場的主要參與者包括：
- 奧林巴斯株式會社（日本）
- Cantel Medical（美國）
- Getinge AB（瑞典）
- STERIS plc（美國）
- Belimed（瑞士）
- STEELCO SpA（義大利）
- ASP（美國）
- BD（美國）
- Crosstex International, Inc.（美國）
- 泰華施公司（美國）
- MMM集團（美國）
- 3M（美國）
- 生物梅里埃公司（法國）
- Sterigenics US, LLC（美國）
- 造父變星（美國）
- Dentsply Sirona（美國）
- 邁瑞生物醫療電子股份有限公司 (中國)
- 朗道實驗室有限公司（英國）
- Ortho Clinical Diagnostics（美國）
- Nova Biomedical（英國）
- Sysmex株式會社（日本）
以上是報告中涵蓋的關鍵參與者，要了解更多醫院獲得性感染控制市場公司聯繫方式的詳盡列表，請訪問 https://www.databridgemarketresearch.com/contact
研究方法：全球醫院獲得性感染控制市場
資料收集和基準年分析是使用具有大樣本量的資料收集模組完成的。使用市場統計和相干模型來分析和估計市場數據。此外，市場佔有率分析和關鍵趨勢分析是市場報告中的主要成功因素。 DBMR 研究團隊使用的關鍵研究方法是資料三角測量，其中涉及資料探勘、資料變數對市場的影響分析以及初步（產業專家）驗證。除此之外，資料模型還包括供應商定位網格、市場時間軸分析、市場概覽和指南、公司定位網格、公司市場份額分析、測量標準、全球與區域以及供應商份額分析。如有進一步疑問，請要求分析師致電。
